vs
Side-by-side financial comparison of Orchid Island Capital, Inc. (ORC) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Orchid Island Capital, Inc. is the larger business by last-quarter revenue ($38.5M vs $28.1M, roughly 1.4× ARS Pharmaceuticals, Inc.). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs -147.1%, a 415.8% gap on every dollar of revenue. On growth, Orchid Island Capital, Inc. posted the faster year-over-year revenue change (372.6% vs -67.6%).
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
ORC vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.5M | $28.1M |
| Net Profit | $103.4M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | — | -147.6% |
| Net Margin | 268.7% | -147.1% |
| Revenue YoY | 372.6% | -67.6% |
| Net Profit YoY | 1764.9% | -182.8% |
| EPS (diluted) | — | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.5M | $28.1M | ||
| Q3 25 | $26.9M | $32.5M | ||
| Q2 25 | $23.2M | $15.7M | ||
| Q1 25 | $19.7M | $8.0M | ||
| Q4 24 | — | $86.6M | ||
| Q3 24 | $340.0K | $2.1M | ||
| Q2 24 | $-697.0K | $500.0K | ||
| Q1 24 | $-2.5M | $0 |
| Q4 25 | $103.4M | $-41.3M | ||
| Q3 25 | $72.1M | $-51.2M | ||
| Q2 25 | $-33.6M | $-44.9M | ||
| Q1 25 | $17.1M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $17.3M | $-19.1M | ||
| Q2 24 | $-5.0M | $-12.5M | ||
| Q1 24 | $19.8M | $-10.3M |
| Q4 25 | — | -147.6% | ||
| Q3 25 | — | -163.7% | ||
| Q2 25 | — | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | — | -3068.0% | ||
| Q1 24 | — | — |
| Q4 25 | 268.7% | -147.1% | ||
| Q3 25 | 267.8% | -157.4% | ||
| Q2 25 | -145.0% | -285.6% | ||
| Q1 25 | 86.9% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 5094.1% | -925.0% | ||
| Q2 24 | 714.3% | -2503.2% | ||
| Q1 24 | -794.2% | — |
| Q4 25 | — | $-0.41 | ||
| Q3 25 | — | $-0.52 | ||
| Q2 25 | — | $-0.46 | ||
| Q1 25 | — | $-0.35 | ||
| Q4 24 | — | $0.52 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $665.9M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $1.4B | $114.3M |
| Total Assets | $11.7B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $665.9M | $245.0M | ||
| Q3 25 | $583.9M | $288.2M | ||
| Q2 25 | $440.8M | $240.1M | ||
| Q1 25 | $396.4M | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | $322.1M | $204.6M | ||
| Q2 24 | $241.0M | $218.7M | ||
| Q1 24 | $190.4M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.4B | $114.3M | ||
| Q3 25 | $1.1B | $147.7M | ||
| Q2 25 | $912.0M | $192.3M | ||
| Q1 25 | $855.9M | $229.0M | ||
| Q4 24 | — | $256.8M | ||
| Q3 24 | $656.0M | $201.0M | ||
| Q2 24 | $555.9M | $215.2M | ||
| Q1 24 | $481.6M | $223.9M |
| Q4 25 | $11.7B | $327.7M | ||
| Q3 25 | $9.1B | $372.8M | ||
| Q2 25 | $7.6B | $313.5M | ||
| Q1 25 | $7.3B | $327.3M | ||
| Q4 24 | — | $351.2M | ||
| Q3 24 | $5.9B | $217.6M | ||
| Q2 24 | $4.9B | $222.0M | ||
| Q1 24 | $4.2B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $120.4M | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $120.4M | $-43.5M | ||
| Q3 25 | $28.0M | $-47.0M | ||
| Q2 25 | $18.4M | $-39.6M | ||
| Q1 25 | $25.8M | $-40.7M | ||
| Q4 24 | — | $42.0M | ||
| Q3 24 | $-14.8M | $-14.5M | ||
| Q2 24 | $19.3M | $-7.3M | ||
| Q1 24 | $45.0M | $-6.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
| Q4 25 | 1.16× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.51× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | -0.86× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ORC
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
